The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Arjan Lalchandani
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.4 pts more than Nifty Microcap 250 and 4.9 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Arjan Lalchandani, the Promoter and Managing Director of Dr Lalchandani Labs Ltd, sold 1,20,000 equity shares of the company through the open market between May 09, 2025 and June 03, 2025. His shareholding dropped from 18,42,851 shares (42.53%) to 17,22,851 shares (39.76%), representing a 2.77% reduction in stake. The disclosure has been filed under Regulation 29(2) of SEBI's Substantial Acquisition of Shares & Takeovers (SAST) Regulations, 2011, which is triggered when a promoter's holding changes by more than 2%. The total equity share capital of the company stood at Rs. 4,33,30,680 and remained unchanged after the transaction.
This is a meaningful promoter sell-off (2.77% of equity) that retail investors should monitor closely, as continued promoter selling can weigh on stock sentiment. However, the promoter still holds a substantial 39.76% stake, indicating continued skin in the game. Watch for any further disclosures or sustained selling patterns.